Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Preserved prostaglandin analog and ocular surface disorders in open angle glaucoma

Poster Details

First Author: A.Shehata EGYPT

Co Author(s):                        

Abstract Details

Purpose:

Long-term use of topical ocular medications may affect ocular surface health. Purpose of this study was to evaluate the influence of BAK-preserved prostaglandin analog (bimatoprost 0.03%) treatment on the ocular surface health in patients with newly diagnosed POAG.

Setting:

Magrabi hospital Riyadh, Saudi Arabia

Methods:

Long-term use of topical ocular medications may affect ocular surface health. Purpose of this study was to evaluate the influence of BAK-preserved prostaglandin analog (bimatoprost 0.03%) treatment on the ocular surface health in patients with newly diagnosed POAG.

Results:

IOP decreased in all patients from baseline to 3-month final visit (24.70 ± 1.65 mmHg versus 15.68 ± 1.68 mmHg). Mean TBUT decreased from 10.71 ± 1.85 seconds at baseline to 7.25 ± 1.21 seconds at 3-month final visit (P<0.001). Mean OSDI score increased from 31.63 ± 18.48 to 44.41 ± 16.48 (P=0.001).

Conclusions:

BAK-preserved bimatoprost 0.03% is an effective medication for IOP control in newly diagnosed POAG patients, but its long-term use may negatively influence ocular surface health by disrupting the tear film stability.

Financial Disclosure:

NONE

Back to Poster listing